Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) plus ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): Identification of TMB cutoff from CheckMate 568 Meeting Abstract
| Authors: | Ramalingam, S. S.; Hellmann, M. D.; Awad, M. M.; Borghaei, H.; Gainor, J.; Brahmer, J.; Spigel, D. R.; Reck, M.; O'Byrne, K. J.; Paz-Ares, L.; Zerba, K.; Li, X.; Geese, W. J.; Green, G.; Lestini, B.; Szustakowski, J. D.; Chang, H.; Ready, N. |
| Abstract Title: | Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) plus ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): Identification of TMB cutoff from CheckMate 568 |
| Meeting Title: | 109th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 78 |
| Issue: | 13 Suppl. |
| Meeting Dates: | 2018 Apr 14-18 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2018-07-01 |
| Language: | English |
| ACCESSION: | WOS:000468818900071 |
| DOI: | 10.1158/1538-7445.Am2018-ct078 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CT078 -- Source: Wos |
